Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD3WNP)

• Drug Name: RO5520985 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMD3WNP

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[3]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[4]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[5]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[6]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[7]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[9]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[10]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[11]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[12]

Drug(s) Targeting Angiopoietin-2 (ANGPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[5]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[13]
Trebananib	DMOG2X1	Ovarian cancer	2C73	Phase 3	[14]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[15]
LY3127804	DMAC457	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[12]
REGN910-3	DMTBRPO	Neovascular age-related macular degeneration	9B78.3Z	Phase 2	[16]
CVX-060	DM03LWZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]
BI 836880	DMRI6YT	Neoplasm	2A00-2F9Z	Phase 1	[18]
CVX-241	DMV74JC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
REGN-910	DMHR7D4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin-2 (ANGPT2)	TTKLQTJ	ANGP2_HUMAN	Modulator	[2]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT02141295) A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
• [2] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [6] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [7] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [8] Clinical pipeline report, company report or official report of Genentech (2009).
• [9] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [10] Bispecific antibodies and their applications
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [14] Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
• [15] Company report (Roche pipeline: July 27, 2017)
• [16] ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
• [17] Clinical pipeline report, company report or official report of CovX (2011).
• [18] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [19] Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
• [20] Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.